Abeona Therapeutics Inc. (NASDAQ:ABEO) traded down 3.2% during trading on Friday . The stock traded as low as $4.14 and last traded at $4.23, with a volume of 97,666 shares changing hands. The stock had previously closed at $4.37.

Several equities research analysts have commented on the stock. FBR & Co reaffirmed a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Sunday, May 22nd. Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Wednesday, April 27th. Maxim Group set a $6.00 price target on Abeona Therapeutics and gave the company a “buy” rating in a research report on Thursday. Finally, Rodman & Renshaw reiterated a “buy” rating and set a $17.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, May 18th.

The firm’s 50 day moving average is $2.91 and its 200 day moving average is $2.73. The company’s market cap is $138.88 million.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.06. On average, equities analysts predict that Abeona Therapeutics Inc. will post ($0.75) EPS for the current year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC raised its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned 0.92% of Abeona Therapeutics worth $1,007,000 at the end of the most recent quarter.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.